Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov
- Address
- lock Available on a paid plan
Oncology and Lung Cancer Research
At Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov, clinical trials in neoplasms focus on advanced non-small cell lung cancer and breast cancer. The studies are designed to test new treatment combinations and compare them with established therapies, with the goal of improving control of advanced disease and extending progression-free survival.
- Advanced non-small cell lung cancer
- ER-positive, HER2-negative advanced breast cancer
- Evaluating new therapy combinations and treatment effectiveness
These studies reflect a strong focus on modern cancer care in the outpatient oncology setting, especially for patients with advanced tumors who need better options after standard treatment.
Cardiovascular and Thromboembolic Disease Studies
Research in cardiovascular diseases at this site includes trials for atrial fibrillation, atherosclerotic cardiovascular disease, and prevention of ischemic stroke. The purpose is to assess whether newer treatments can better prevent clot-related complications and reduce major cardiovascular events.
- Atrial fibrillation
- Atherosclerotic cardiovascular disease
- Preventing stroke and other embolic events
These investigations aim to improve long-term protection for patients at risk of serious heart- and brain-related complications.
Immunology and Inflammatory Disease Research
Trials in immune system diseases and related inflammatory conditions include atopic dermatitis, hidradenitis suppurativa, and chronic inflammatory demyelinating polyneuropathy. The main objective is to evaluate how well new therapies control symptoms, maintain response, and support safer long-term management of chronic inflammation.
- Atopic dermatitis
- Hidradenitis suppurativa
- Chronic inflammatory demyelinating polyneuropathy
This area shows a broad interest in improving treatment options for immune-mediated disorders that can significantly affect daily life and quality of care.
Skin and Hair Disorder Research
The site also studies skin and connective tissue diseases such as vitiligo and alopecia areata. These trials are intended to measure whether new therapies can improve visible symptoms, support disease control, and offer more durable benefit for patients with chronic dermatologic conditions.
- Non-segmental vitiligo
- Alopecia areata
- Testing treatments that may improve symptoms and patient-reported outcomes
Research in this area combines clinical effectiveness with a focus on conditions that often have a major emotional and social impact.
Neurology and Peripheral Nerve Disease Trials
Within nervous system diseases, the site is involved in studies for chronic inflammatory demyelinating polyneuropathy. These trials are aimed at evaluating therapies that may help prevent relapse, preserve neurological function, and maintain response in patients living with this long-term disorder.
- Chronic inflammatory demyelinating polyneuropathy
- Preventing relapse and maintaining clinical response
- Assessing long-term safety and effectiveness
This research supports better management strategies for patients with ongoing nerve-related weakness and disability.
Metabolic, Kidney, and Inflammation-Focused Research
Trials in nutritional and metabolic diseases and related systemic conditions examine cancer cachexia and chronic kidney disease with systemic inflammation. The studies are designed to explore whether new therapies can improve body weight, appetite-related symptoms, and broader inflammatory risk.
- Cancer cachexia
- Chronic kidney disease with systemic inflammation
- Supporting symptom control and reducing disease burden
These trials highlight interest in conditions where inflammation and nutritional decline can strongly affect outcomes and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Zenas Biopharma (USA) LLC2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunovant Sciences GmbH3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fakultna Nemocnica S Poliklinikou J. A. Reimana Presov
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione | 2 | Unknown | 2023-06-05 | 2023-10-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.